Presentation Vaatdagen | Mar 18th 2019
Results of the First-In-Man clincial study will be presented by Daniel Eefting MD, Principal Investigator of the study
Company move | Dec 2019
Approval Clinical study | Jan 2020
In December TripleMed moved to the new location on the Brightlands Chemelot Campus.
Next to additional office space , the new location contains a R&D lab and ISO7 clean production facilities
With this TripleMed is ready to expand their activities towards commercialization of AneuFix / AneuFill
End of January the METC approval for the type II endoelak study is expected to be received, after which the clinical study will start.
CA/EC requests for approvals in France, Germany and Belgium are ongoing
Presentation Veith Congress New York | Nov 23rd 2018
On November 23rd the preliminary results of the First-In-Man clinical study were presented at the Veith Congress by Prof. Jacobs.
TripleMed secures 2M funding | Sep 21st 2017
TripleMed raises over €2 million for innovative treatment of aortic aneurysms